Addyi

Chemical Nameflibanserin
Dosage FormTablet (oral; 100 mg)
Drug ClassReceptor agonists
SystemFemale reproductive
CompanySprout Pharms
Approval Year2015

Indication

  • For the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: 1, A co-existing medical or psychiatric condition, 2, Problems within the relationship, or 3, The effects of a medication or other drug substance.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Addyi (flibanserin) Prescribing Information2019Sprout Pharmaceuticals, Inc., Raleigh, NC